As an example, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as gefitinib (IRESSA) and erlotinib (TARCEVA) are established treatments for advanced non-small-cell lung cancer (NSCLC) in Asia (Han et al. 2014; Kato et al. 2011; Mok et al. 2009). Here, EGFR is linked to non-small cell lung carcinoma.